ErbB3/Her3 Antibody [ADC] - (Patritumab Deruxtecan, Research Grade)

Immobilized human HER3 His at 2 ug/mL can bind ErbB3/Her3 (Patritumab Deruxtecan) Antibody, EC50=0.044 ug/mL.

• Reactivity: Hu
• Applications: ELISA, Flow, Func
• Clonality: Monoclonal
• Host: Human
• Conjugate: ADC
• Concentration: LYOPH

ErbB3/Her3 Antibody [ADC] - (Patritumab Deruxtecan, Research Grade) Summary

• Description: This product is an Antibody-Drug Conjugate (ADC) for Research Use Only (RUO).
  
  ErbB3/Her3 (Patritumab Deruxtecan) Antibody is a novel ADC composed of an anti-HER3 antibody (Patritumab) and a novel potent topoisomerase I inhibitor DX-8951,conjugated, on an average of 8 cysteinyl, to deruxtecan, comprising a linker and a camptothecin derivative.
  
  This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
• Immunogen: ErbB3/Her3 (Uniprot: P21860)
• Source: CHO
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Human
• Purity: > 90% by SDS-PAGE and HPLC

Applications/Dilutions

• Dilutions:
  • ELISA
  • Flow Cytometry
  • Functional
• Theoretical MW: 155.2 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -20C in powder form. Store at -80C once reconstituted.
• Buffer: Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: > 90% by SDS-PAGE and HPLC
• Reconstitution Instructions: Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Alternate Names for ErbB3/Her3 Antibody [ADC] - (Patritumab Deruxtecan, Research Grade)

• c-erbB3
• EC 2.7.10
• EC 2.7.10.1
• ErbB3
• ErbB-3
• erbB3-S
• HER3
• HER3c-erbB-3
• LCCS2
• lethal congenital contracture syndrome 2
• MDA-BF-1
• MGC88033
• p180-ErbB3
• p45-sErbB3
• p85-sErbB3
• Proto-oncogene-like protein c-ErbB-3
• receptor tyrosine-protein kinase erbB-3
• Tyrosine kinase-type cell surface receptor HER3
• v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)

Background

The ErbB3 gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. ErbB3 is a membrane-bound protein which has a neuregulin binding domain but not an active kinase domain. It can therefore bind this ligand but cannot convey a signal into the cell via protein phosphorylation. However it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers including prostate, bladder and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported but they have not been thoroughly characterized.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.